Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;17(2):255-62.
doi: 10.1007/s10120-013-0279-1. Epub 2013 Jul 5.

Mortalin is a prognostic factor of gastric cancer with normal p53 function

Koji Ando  1 , Eiji Oki, Yan Zhao, Ayae Ikawa-Yoshida, Hiroyuki Kitao, Hiroshi Saeki, Yasue Kimura, Satoshi Ida, Masaru Morita, Tetsuya Kusumoto, Yoshihiko Maehara
Affiliations

Mortalin is a prognostic factor of gastric cancer with normal p53 function

Koji Ando et al. Gastric Cancer. 2014 Apr.

Abstract

Background: Mortalin is a heat-non-inducible member of the heat shock protein 70 family. Mortalin binds to p53 and prevents p53 from entering the nucleus. To understand the significance of mortalin in gastric cancer, we investigated the expression of mortalin and p53.

Methods: Expression of mortalin and p53 was examined by immunohistochemical staining of 182 clinical samples of gastric cancer.

Results: Mortalin-positive and aberrant p53-positive tumors were found in 75.2 and 49.5 % of cases, respectively. Mortalin-positive tumors were deeper in invasion and had more lymph node and liver metastases compared with mortalin-negative tumors (P < 0.01, P < 0.05, respectively). Mortalin-positive tumors had worse prognosis compared with mortalin-negative tumors (P = 0.035). Moreover, in tumors with normal p53 function, mortalin-positive tumors had worse prognosis compared with mortalin-negative tumors (P = 0.017).

Conclusions: Mortalin has a great impact on gastric cancer with normal p53. Therefore, mortalin is a target molecule for treatment of gastric cancer, as well as a promising prognostic factor, especially in tumors with normal p53.

PubMed Disclaimer

References

    1. Mol Cell Biochem. 2005 Jan;268(1-2):45-51 - PubMed
    1. Biochem J. 1999 Oct 15;343 Pt 2:461-6 - PubMed
    1. Exp Cell Res. 2002 Apr 1;274(2):246-53 - PubMed
    1. Cancer Res. 1998 Sep 15;58(18):4023-37 - PubMed
    1. J Gene Med. 2004 Apr;6(4):439-44 - PubMed

MeSH terms